# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
NeuroMetrix, Inc. (NASDAQ:NURO) today for the purpose of clarity, reiterated that the Company is engaged in a review of strateg...
NeuroMetrix (NASDAQ:NURO) reported quarterly losses of $(0.74) per share. This is a 51.32 percent increase over losses of $(1.5...
NeuroMetrix (NASDAQ:NURO) reported quarterly losses of $(1.67) per share. This is a 1.83 percent decrease over losses of $(1.64...
NeuroMetrix, Inc. (NASDAQ:NURO) today announced that over 2000 fibromyalgia patients have been prescribed Quell Fibromyalgia si...
- Stock trades significantly below its net cash per share- Questions the Board's ability and/or desire to create shareholde...